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the Board, and pays all outstanding fees.
This bill was signed by the Governor on
March 30 (Chapter 26, Statutes of 1994).
AB 2020 (Isenberg), as amended April
28, is a COA-sponsored bill which would
provide that the practice of optometry includes, among other things, the examination of the human eye, or its appendages
and adnexa, and the analysis and diagnosis of conditions of the human vision system, either subjectively or objectively;
and authorize optometrists to use specified diagnostic pharmaceutical agents. It
would also authorize optometrists who
meet specified requirements to use, prescribe, and dispense specified therapeutic
pharmaceutical agents to a patient for the
purposes of treating the human eye, or its
appendages or adnexa, for any disease or
pathological condition. The bill would establish a seven-member pharmaceutical
advisory committee with a prescribed
membership to provide advice to the
Board as to the use of diagnostic and therapeutic agents by optometrists. Under this
bill, only optometrists who meet several
examination and training requirements
and agree to accept Medi-Cal patients are
permitted to use, dispense, or prescribe
therapeutic pharmaceutical agents. AB
2020 would also make it a misdemeanor
for any person licensed as an optometrist
to refer a patient to a pharmacy that is
owned by the licensee or in which the
licensee has a proprietary interest; and
require Board licensees to complete, at a
minimum, 25 hours of continuing education per year, one-third of which must
relate to the diagnosis, treatment, and
management of ocular disease. [S. B&P]
AB 1894 (Polanco), as amended January 14, would authorize ancillary personnel who work under the supervision of an
optometrist to assist in the preparation of
the patient and the preliminary collection
of data that does not require the exercise
of professional judgment or the skill of an
optometrist and is limited to specified activities; the bill would provide that ancillary personnel are not authorized to perform any data analysis or diagnosis, or to
prescribe and determine any treatment
plan. [S. B&P]
SB 908 (Calderon), as introduced
March 4, 1993, would provide that the
terms "license" and "certificate of registration" are deemed to be synonymous for
the purposes of the provisions of law regarding the licensure and regulation of
optometry. [A. Inactive File]
SB 921 (Maddy), which would have
provided that it is unprofessional conduct
for an optometrist to fail to advise a patient
in writing of any pathology that requires
the attention of a physician when an ex-

amination of the eyes indicates a substantial likelihood of any pathology, died in
committee.

ident, Jennifer H.W. Hao, OD, as vicepresident, and R. Mona Tawatao to serve
as secretary.
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LITIGATION

In Engineers and Scientists of California (ESC), et al. v. Division of Allied
Health Professions (DAHP), Medical
Board of California, No. 532588, following a one-day trial conducted on April 25,
Sacramento County Superior Court Judge
Rudolph Loncke ruled in favor of plaintiffs ESC and COA by invalidating two
subsections of DAHP's medical assistant
regulations which-according to ESC and
COA-permit unlicensed medical assistants to perform optometric tasks and
functions. [14:1 CRLR 72; 13:2&3 CRLR
100] The court found fault with DAHP's
procedure in adopting the regulations, and
did not reach the merits of ESC/COA's
claim.
Specifically, the court ruled that the
following two portions of section 1366,
Title 16 of the CCR, are invalid and ineffective: (1) section 1366(b)(4), which provided that medical assistants may perform
automated visual field testing, tonometry, or
other simple or automated ophthalmic testing not requiring interpretation in order to
obtain test results, using machines or instruments, but are precluded from the exercise
of any judgment or interpretation of the data
obtained on the part of the operator; and (2)
that part of section 1366(d) which referred
to section 1366(b)(4). After removing the
objectionable portion of section 1366(d),
that section now provides that "[n]othing
in these regulations shall be construed to
authorize a medical assistant to practice
optometry." The offensive sections were
added at the final public hearing on the
proposed rules and released as a "nonsubstantive change" for a 15-day public
comment period; the court found that the
changes were substantive and should have
been republished for a full 45-day public
comment period.
The court restrained and enjoined DAHP
from enforcing the invalid provisions; ordered DAHP to immediately inform, in
writing, the Secretary of State of the invalidity of those provisions; directed the Secretary of State to publish the same notice
in the CaliforniaRegulatory Notice Register,and ordered DAHP to forthwith notify, in writing, all medical licentiates, podiatry licentiates, and all known medical
assistants of the invalidity of those provisions. At this writing, it is unknown whether
DAHP will appeal the court's ruling.

U

RECENT MEETINGS
At its March meeting, the Board elected
John Anthony, OD, to serve as Board pres-

FUTURE MEETINGS
May 19-20 in San Francisco.
August 18-19 in Sacramento.

BOARD OF PHARMACY
Executive Officer: PatriciaHarris
(916) 445-5014
Dursuant to Business and Professions
Code section 4000 et seq., the Board
of Pharmacy grants licenses and permits
to pharmacists, pharmacies, drug manufacturers, wholesalers, and sellers of hypodermic needles. It regulates all sales of
dangerous drugs, controlled substances,
and poisons. The Board is authorized to
adopt regulations, which are codified in
Division 17, Title 16 of the California
Code of Regulations (CCR). To enforce its
regulations, the Board employs full-time
inspectors who investigate complaints received by the Board. Investigations may
be conducted openly or covertly as the
situation demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized by
law to suspend or revoke licenses or permits for a variety of reasons, including
professional misconduct and any acts substantially related to the practice of pharmacy.
The Board consists of ten members,
three of whom are nonlicensees. The remaining members are pharmacists, five of
whom must be active practitioners. All are
appointed for four-year terms.
In January, public member Herb Strickline resigned from the Board; at this writing, he has not yet been replaced.

U

MAJOR PROJECTS

Oral Consultation Regulations. At
the Board's January 26-27 meeting, Executive Officer Patricia Harris reported on
the Board's enforcement of its oral consultation regulations which have been in effect since November 1, 1992. Under sections 1707.1 and 1707.2, Title 16 of the
CCR, pharmacists must maintain patient
medication profiles on all ongoing patient-consumers and provide an oral consultation to each patient or patient's agent
whenever a new prescription is dispensed,
with specified exceptions. [12:4 CR1B
115-16; 12:2&3 CRLR 135]
Although she acknowledged a common perception that the Board has not
been enforcing the regulations, Harris
stated that the Board has been enforcing
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them. The Board allowed for a one-year
transitional education phase prior to the
time it began issuing violation notices because, according to Harris, the majority of
pharmacies were not adequately prepared
to implement this major practice change,
even though the Board delayed the implementation date of the regulations twice
and also adopted pharmacy technician
regulations to assist licensees with staffing problems which might be occasioned
by the oral consultation requirement.
Harris also noted that many pharmacists who work at chain drugstores have
informed the Board that they are having
difficulty complying with the oral consultation mandate as written. According to
these pharmacists, they are caught between the state's requirement to provide
oral consultation and their employers'
right to determine the amount of staffing
within each pharmacy. Following discussion of several options for addressing the
concerns of the chain pharmacists, the
Board unanimously passed a motion stating Board policy that enforcement of the
oral consultation requirement is a priority,
and directed that pharmacy owners, pharmacists-in-charge, and pharmacists be
held responsible for compliance. Also, the
Board agreed that when violations occur,
its Northern and Southern Interim Committees are to consider all circumstances
contributing to the violation and take appropriate action.
In a related January agenda item, the
Board heard from representatives of the
University of Southern California (USC)
School of Pharmacy and Kaiser Permanente, who presented the fifth quarterly
report on the joint Kaiser-USC study on
the effects of the oral consultation requirement in the outpatient setting. In June
1992, the Board granted Kaiser an exemption from the oral consultation requirement in all of its facilities, and instead
allowed it to implement a research model
to compare the effects of three different
consultation and pharmacy practice models on patient health outcomes, medication
compliance, and resource utilization.
[12:4 CRLR 116] Kaiser's exemption was
scheduled to be in effect for two years
from the scheduled implementation date
of November 1, 1992. However, due to
difficulties in getting the necessary personnel trained and in place, the project did
not become fully operational until April 1,
1993; as a result, the Kaiser officials appeared before the Board at its January
meeting to ask the Board to extend the
waiver for an additional five months, continuing Kaiser's exemption until April 1,
1995. Following discussion, the Board
voted 4-3, with two abstentions, to grant

Kaiser the five-month extension on its exemption from the oral consultation requirement.
Also at its January meeting, the Board
considered a request from the California
Pharmacists Association (CPhA) that it
implement SB 1051 (McCorquodale)
(Chapter 763, Statutes of 1993), which
requires the Board to adopt regulations
that apply the same requirements or standards for oral consultation to out-of-state
pharmacies as are applied to in-state pharmacies. [13:4 CRLR 80-81] Specifically,
CPhA asked the Board to amend section
1707.2, Title 16 of the CCR, to require all
pharmacies (in-state and out-of-state)
which ship, deliver, or mail prescriptions
to California residents to make a reasonable attempt to contact the patient and
provide oral consultation over the telephone. Additionally, CPhA's proposed
amendments would provide that when,
after a reasonable attempt, the pharmacy
is unable to provide oral consultation, and
further attempts to contact the patient or
agent would result in an unnecessary delay
in receipt of the medication by the patient,
the pharmacy shall document the reasonable attempt(s) made to contact the patient
or agent; ensure that the patient or agent
receives written notice of his/her right to
oral consultation by a pharmacist; provide
the patient or agent with written consultation that is equivalent to the oral consultation required by section 1707.2(c); and provide written notice of a telephone number
from which the patient may obtain oral
consultation from a pharmacist who has
ready access to the patient's record. Following discussion, the Board agreed by a
6-2 vote to pursue the proposed amendments to section 1707.2, and tentatively
set the regulatory hearing for its July meeting.
At its March 30-31 meeting, the Board
heard from representatives of Caremark,
Inc., a mail order pharmacy which fills ten
million prescriptions per year, who contended that CPhA's proposed amendments
to section 1707.2 are not an effective way to
communicate with patients, and requested
that the Board review an alternative approach. The Board also heard from a representative of the American Association of
Retired Persons' Pharmacy Service, who
contended that CPhA's proposed amendments are not authorized by SB 1051; they
raise constitutional concerns because they
excessively impact interstate commerce
[12:2&3 CRLR 134]; and they are unnecessary, overly burdensome on nonresident
pharmacies, and inconsistent with factual
evidence presented to the Board in previous public hearings on the oral consultation issue. Following discussion, the
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Board considered a motion to postpone
the regulatory hearing on CPhA's proposed amendments to section 1707.2, and
form a subcommittee to determine an appropriate substitution for oral consultation
for nonresident pharmacies that ship, deliver, or mail prescriptions to California
patients; that motion was rejected by a 5-3
vote. Thus, on May 13, the Board published notice of its intent to pursue the
amendment; at this writing, the public
hearing is scheduled for July 28.
Also at the Board's March meeting,
Board President Raffi Simonian stated
that the Board would continue to address
the oral consultation regulations at each
meeting until they are appropriately followed by pharmacists; Simonian announced
that the Board's inspectors have been directed to enforce the regulations. The
Board directed staff to provide for the
Board's review at each meeting the total
number of correction orders issued by
Board inspectors for failure to provide
oral consultation, maintain patient profiles, or review patient profiles prior to
dispensing to patients; chain stores, community pharmacies, and hospitals will be
tracked separately.
Rulemaking Update. The following
is a status report on Board rulemaking
proposals discussed in detail in previous
issues of the Reporter:
• Because the Board's Enforcement
Committee was disbanded, it was unable
to review the proposed citation and fine
regulations as directed by the Board after
a contentious public hearing at its October
1993 meeting. [14:1 CRLR 73] However,
the Board continued its review of the proposed regulations at its March meeting, at
which time it unanimously agreed to the
concept of a citation and fine program to
implement its authority under section 125.9
of the Business and Professions Code. In
order to improve compliance with the oral
consultation requirement (see above), the
Board decided to modify the proposed
language to authorize its Northern and
Southern Interim Committees to issue citations and fines, and to review all the
public comments received at the October
1993 hearing to determine if further modifications are necessary. At this writing,
the Board is scheduled to review the proposed citation and fine regulations at its
May 25 meeting.
, At its January 26 meeting, the Board
held a public hearing on its proposed
adoption of section 1751.11, Title 16 of
the CCR, which would (among other
things) establish a list of dangerous drugs
which may be furnished by a pharmacist
to a licensed home health agency and
stored in transportable, tamper-proof,
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sealed storage containers. [14:1 CRLR 73;
13:4 CRLR 82] At the hearing, the Board
received testimony encouraging the expansion of the list of drugs which may be
included in the kit from CPhA, the California Nurses Association, the Home Infusion Therapy Coalition of California, the
California Society of Hospital Pharmacists, Critical Care America, and the California Association for Health Services at
Home. Many of the hearing participants
stated that an expanded list of drugs would
allow for the immediate treatment of emergency situations more effectively and efficiently, make it possible to better meet the
needs of the various patient populations
served, make it easier to provide early
treatment and prevent hospitalization and
emergency room visits, and allow for the
anticipated growth in home health care.
Gilbert Castillo, former Board President
and registered pharmacist, testified in support of the proposal and urged the Board
to adopt the regulation as proposed. According to Castillo, the regulation as originally drafted would accomplish the goal
of providing a method by which registered
nurses employed by a home health agency
could have emergency access to dangerous drugs necessary for the delivery of
parental therapy in the alternative setting.
After discussion, the Board agreed to
pursue the regulatory action, subject to
various revisions. Among the changes was
the addition of proposed section 1751.12,
which would provide that a licensed pharmacy shall not issue portable containers to
any home health agency or licensed hospice unless the pharmacy has secured reasonable assurance from the home health
agency or licensed hospice that it will comply with provisions of section 1751.11, and
prohibit a licensed pharmacy from furnishing portable containers to a home health
agency or licensed hospice if it does not
comply with the provisions of section
1751.11. The Board's changes also added
normal saline to the list of drugs which
may be included in the portable container.
In mid-February, the Board released the
modified language for an additional 15day public comment period.
At its March meeting, the Board discussed the various comments it received
during the 15-day public comment period.
Following discussion, the Board made
several more changes to the proposal, including the addition of a number of drugs
to the list of drugs which may be included
in the portable container, and revision of the
language to clarify that it is the pharmacy's
responsibility to ensure that specified requirements are met. The Board unanimously adopted the modifications and
agreed to release them for an additional
96

15-day public comment period; at this
writing, the Board hopes to finalize the
adoption of the provisions at its May 25
meeting.
- On January 7, the Office of Administrative Law approved the Board's amendment to section 1732.3, Title 16 of the
CCR, which provides that a recognized
continuing education provider's coursework shall be valid for three years following initial Board approval; previously,
such coursework was valid for two years
following initial Board approval. [14:1
CRLR 74; 13:4 CRLR 79]
- On March 11, the Board published
notice of its intent to completely revise
section 1724, Title 16 of the CCR, which
currently provides that in order to pass the
pharmacist licensure examination, a candidate must achieve a score of 75 or more
on each section, and that a candidate who
receives a score of less than 75 on one
section only may retake that one section
only at the next scheduled examination;
however, if that candidate exercises this
option and fails to achieve a score of 75 or
more, he/she must take the entire examination upon the next application. [14:1
CRLR 74] The Board's proposed new language for section 1724 would provide that
the Board's examination consists of two
sections, one multiple choice and one
essay, both of which must be passed; any
candidate who receives a failing grade on
the multiple choice section shall be given
a failing grade for the entire examination
without regard to the performance on the
essay section. According to the Board, this
regulatory change is being proposed to
streamline the examination and grading
process; the Board believes that elimination of essay section hand scoring for candidates who fail the multiple choice section will reduce the time and cost for expert graders and related travel expenses.
Although not written into the regulation,
the Board's initial statement of reasons
also states that it will provide, for the first
time, diagnostic reports to candidates who
fail the multiple choice section of the
exam. At this writing, the Board is scheduled to hold a public hearing on its proposed amendments to section 1724 on
May 26 in Sacramento.
Controlled Substance Prescriptions.
Pursuant to 21 C.F.R. Part 1304.04, pharmacists are required to stamp a red "C" on
the hard copy of controlled substance prescriptions. In an effort to accommodate
the extensive use of computers in pharmacies, the Board recently asked the U.S.
Drug Enforcement Agency (DEA) to
modify its regulations to allow pharmacies to either (i) maintain a separate electronic file of Schedule IH-V controlled

substances; (2) maintain a separate physical file of Schedule III-V controlled substances; or (3) mark all Schedule III-V
controlled substance prescriptions with a
red "C." Last fall, DEA responded that
pharmacies have only two options: keep
controlled substance prescriptions physically separate from other prescriptions, or
commingle these and other prescriptions,
in which case a red "C" must be stamped
on controlled substance prescriptions.
[14:1 CRLR 75]
However, a February 1 letter from G.
Thomas Gitchel of DEA acknowledged
that "current requirements under Title 21,
Code of Federal Regulations, Section
1304.04(h)(2), may be somewhat dated,
given the increasing use of electronic processing systems in pharmacies." Gitchel
noted that DEA has "initiated a study of
the use of computers in pharmacy activities with the intent of determining what
provisions might be made in the regulations for use of such systems." To that end,
Gitchel requested that the Board describe
its experiences with allowing computerized prescription recordkeeping systems.
At its March 30 meeting, the Board agreed
to furnish such information to DEA.
LEGISLATION
SB 2036 (McCorquodale), as amended
May 18, would create a "sunset" review
process for occupational licensing agencies within the Department of Consumer
Affairs (DCA), requiring each to be comprehensively reviewed every four years.
SB 2036 would impose an initial "sunset"
date of July 1, 1998 for the Board; create
a Joint Legislative Sunset Review Committee within the legislature, which would
review the Board's performance approximately one year prior to its sunset date;
and specify 11 categories of criteria under
which the Board's performance will be
evaluated. Following review of the agency
and a public hearing, the Committee
would make recommendations to the
legislature on whether the Board should
be abolished, restructured, or redirected in
terms of its statutory authority and priorities. The legislature may then either allow
the sunset date to pass (in which case the
Board would cease to exist and its powers
and duties would transfer to DCA) or pass
legislation extending the sunset date for
another four years. (See agency report on
DCAfor related discussion of the "sunset"
concept.) [S. Appr]
SB 2045 (Petris), as introduced February 25, would specify that a pharmacist is
liable to a parent or other caregiver of a
patient incapable of taking medication
without assistance, as specified, if the
pharmacist knows this fact and the fact
*
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that the medication is to be administered
by the parent or caregiver, and mislabels
the dosage of a prescription medication or
otherwise incorrectly fills or mislabels a
prescription. The bill would expressly
overrule the California Supreme Court's
decision in Huggins v. Longs Drug Stores
California,Inc., 6 Cal. 4th 124 (Nov. 18,
1993). [14:1 CRLR 751 [S. Floor]
AB 2973 (Aguiar). The Pharmacy
Law regulates the licensure of pharmacies
and medical device retailers and includes,
among other things, provisions requiring
that certificates, licenses, permits, or registrations for these businesses be obtained
and renewed by persons conducting these
businesses in compliance with certain application procedures; existing law requires the Board to issue temporary permits upon conditions determined by the
Board when the ownership of these businesses is transferred and authorizes the
Board, under certain circumstances, to
void the licenses of these businesses and
obtain a court order authorizing the Board
to enter the premises of these businesses
and arrange for the transfer or sale of
dangerous drugs, controlled substances,
or dangerous devices found therein. As
amended April 25, this bill would expand
the Board's jurisdiction by making several
of these provisions regulating pharmacies
and medical device retailers also applicable to veterinary food-animal drug retailers.
Existing law provides that a dangerous
drug, as defined, does not include a veterinary drug that is labeled as a veterinary
drug. This bill would, notwithstanding
this provision, provide that veterinary
food-animal drugs include any dangerous
drug intended for use in food-producing
animals that by federal or state law may be
lawfully dispensed only by prescription or
furnished pursuant to certain requirements. [A. Floor]
AB 3173 (Snyder). Existing law permits pharmacists practicing in hospitals to
perform four specified'functions which
may not be performed by pharmacists in
non-hospital settings. As amended May
10, this bill would provide that these functions may also be performed by pharmacists as part of the care provided by a
clinic, home health agency, or a provider
who contracts with a licensed health care
service plan. It would authorize pharmacists to perform these functions only as
part of a multidisciplinary team that includes physicians and direct care registered nurses. [S. B&P]
SB 1759 (Kopp) is similar to AB 3173
(see above). As amended April 27, this bill
would provide that a registered pharmacist is not prohibited from requesting drug

therapy-related laboratory tests or adjusting the drug regimen of a patient pursuant
to a preexisting order or authorization
made by the patient's prescriber in a health
care facility in accordance with policies,
procedures, or protocols developed by
health professionals, provided that the
pharmacist has successfully completed a
certification program approved by the
Board of Pharmacy; define the term
"health care facility" for these purposes as
a facility operated by a health care service
plan; and require that these policies, procedures, or protocols include requirements that the medical records of the patient be available to both the patient's prescriber and the licensed pharmacist, and
that the procedures to be performed by a
licensed pharmacist relate to a condition
for which the patient has already seen a
physician. [S. B&P]
AB 3388 (Harvey). Existing law states
that no provision of law shall be construed
as prohibiting a pharmacy from furnishing
a prescription drug or device to a licensed
health care facility for storage in a prescribed manner. As amended May 5, this
bill would require that these supplies furnished by a pharmacy to licensed health
facilities for storage in a prescribed manner be approved by the facility's patient
care policy committee or pharmaceutical
service committee and be readily available to each nursing station. [A. Floor]
SB 1364 (Marks). Under existing law,
controlled substances that are classified as
Schedule I substances are not authorized
to be used for legitimate medical purposes. As introduced February 1,this bill
would make legislative findings and declarations and would provide that marijuana is deemed a Schedule II substance
for use for legitimate medical purposes.
[S. Floor]
SB 1427 (Mello). Existing law authorizes a pharmacist, when filling a prescription drug order, to select another drug
product with the same active chemical
ingredients of the same strength, quantity,
and dosage form, and of the same generic
drug type, as defined, under certain circumstances. As amended May 16, this bill
would define the term "dosage form" for
purposes of this provision. This bill would
authorize a pharmacist, notwithstanding
that definition, and except when the prescriber indicates no substitutions may be
made, to substitute one drug product for
another drug product if the drug products
are classified as both pharmaceutically
equivalent and therapeutically equivalent
in a specified federal publication. [S.
Floor]
SB 1642 (Craven), as amended April
25, would authorize a licensed physician
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approved to supervise a physician assistant (PA) to delegate to a PA under his/her
supervision, and in a manner determined
by the supervising physician, the authority
to administer or provide medication to a
patient or transmit a prescription from the
supervising physician to a person who
may lawfully furnish the medication or
medical device to the patient. It would
require, prior to delegating prescription
transmittal authority to a PA, the supervising physician to adopt a written, practicespecific formulary and protocols that
specify all criteria to be considered for use
of a particular drug or device, and any
contraindications for the drug or device.
The bill would require any supervising
physician's prescription that is transmitted
by the PA to be based on either the
physician's order for the particular patient
or for a drug listed in the formulary. It
would prohibit a PA from administering,
providing, or transmitting a prescription
for Schedule II through Schedule V controlled substances without an order from
the supervising physician. The bill would
impose other requirements regarding the
content of the prescription transmittal
order. It would provide that when transmitting a prescription, the PA is acting on
behalf of and as an agent for the supervising physician. [S. Floor]
SB 2087 (Mello). SB 1051 (McCorquodale) (Chapter 763, Statutes of 1993)
requires the Board to adopt regulations
that apply the same requirements or standards for oral consultation to an out-ofstate pharmacy that ships, mails, or delivers controlled substances or dangerous
drugs or devices to a resident of this state,
as are applied to an in-state pharmacy
when the pharmacy ships, mails, or delivers any controlled substances or dangerous drugs or devices to a resident of this
state (see MAJOR PROJECTS). As introduced February 25, SB 2087 would repeal
SB 1051's requirement that the Board
adopt regulations and instead would require any pharmacy, whether located in
this state or outside this state, that ships,
mails, or delivers a prescription medication to a resident of this state to provide a
toll-free telephone service during normal
business hours for patients to receive oral
consultation from a pharmacist who has
access to the patient's records. It would
require that written notice of the right to
oral consultation and the toll-free telephone number be provided with each container of drugs that is shipped, mailed, or
delivered to a patient in this state. [S.
Floor]
AB 2610 (Bronshvag), as amended
April 26, would establish the Clean Needle and Syringe Exchange Program, and
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authorize pharmacists, physicians, and
certain persons authorized under the pilot
project to furnish hypodermic needles and
syringes without a prescription or permit
as prescribed through the program. This
bill would state the findings and declarations of the legislature regarding HIV infection and development of AIDS among
injection drug users. [A. W&MJ
The following is a status update on
bills reported in detail in CRLR Vol. 14,
No. I (Winter 1994) at pages 74-75:
SB 1048 (Watson), as introduced March
5, 1993, would establish the Clean Needle
and Syringe Exchange Pilot Project, and
authorize pharmacists, physicians, and certain other persons to furnish hypodermic
needles and syringes without a prescription or permit as prescribed through the
pilot project. [A. Health]
SB 849 (Bergeson). Under the Pharmacy Law, a "hospital pharmacy" means
and includes a pharmacy licensed by the
Board of Pharmacy located within any
hospital, institution, or establishment that
maintains and operates organized inpatient facilities for the diagnosis, care, and
treatment of human illnesses in accordance with certain requirements. Existing
law requires the Department of Health
Services to issue a single consolidated license to a general acute care hospital that
meets certain requirements. As amended
May 11, this bill would permit, under certain conditions, a hospital pharmacy to be
located outside of the hospital in a physical
plant that is regulated under a hospital's
consolidated license. [A. Health]
AB 1807 (Bronshvag), as amended
March 23, provides that, notwithstanding
specified security measures, a medical device retailer may establish a locked facility
for furnishing dangerous devices in emergencies or after working hours, and allows
the Board to authorize revisions in the
security measures pertaining to the delivery of dangerous devices from locked storage to patients.
Existing law defines the term "prescription" for the purposes of existing law
relating to licensure of pharmacists, regulation of pharmacies, and regulation of
controlled substances. This bill revises the
definition of the term prescription, for
those purposes, to also include electronically transmitted prescriptions, as defined.
[13:2&3 CRLR 100-01]
This bill also provides that any order
for a Schedule II controlled substance in a
licensed skilled nursing facility, intermediate health care facility, or a licensed
home health agency providing hospice
care may be dispensed upon an oral or
electronically transmitted prescription;
and requires these facilities to forward to

the dispensing pharmacist a copy.of any
signed telephone order, chart order, or related documentation substantiating each
oral prescription transaction. This bill was
signed by the Governor on March 30
(Chapter 26, Statutes of 1994).
AB 2020 (Isenberg), as amended
April 28, would, among other things, authorize optometrists to use, prescribe, and
dispense specified pharmaceutical compounds to a patient; provide that any use,
prescribing, or dispensing of a pharmaceutical agent to a patient by an optometrist pursuant to these provisions is limited
to that which is incidental to the practice
of optometry; specify that dispensing by
the optometrist to a patient be without
charge; and make it a misdemeanor for
any person licensed as an optometrist to
refer a patient to a pharmacy that is owned
by that licensee or in which the licensee
has proprietary interest. [S. B&P]
AB 667 (Boland), which would have
provided that existing law prohibiting a
person from furnishing any dangerous device, except upon the prescription of a
physician, dentist, podiatrist, or veterinarian, does not apply to the furnishing of any
dangerous device by a manufacturer,
wholesaler, or pharmacy to a chiropractor
acting within the scope of his/her license,
died in committee.

*

RECENT MEETINGS

At the Board's January 26-27 meeting,
staff reported on the status of its request
that the Department of Health Services
(DHS) permit an increase in the number
of different oral drugs which may be
stored in the emergency drug supply of a
licensed skilled nursing facility. Currently, DHS permits six drugs and allows
flexibility for up to twelve drugs; on the
recommendation of its Long-Term Care
Committee, the Board requested that DHS
allow flexibility for up to 24 drugs. At its
October meeting, the Board noted that
DHS denied the request but agreed to consider further requests on a case-by-case
basis. Further, the Board asked whether
DHS would allow the twelve drugs to vary
from nursing station to nursing station
within a facility. [14:1 CRLR 75] At the
January meeting, staff reported that, according to DHS, the same drugs must be
maintained in the same emergency kit
throughout the facility and, in order to
increase that amount, program flexibility
must be pursued. A CPhA representative
commented that its Long-Term Care Management Council is preparing legislation
to address this issue.
Also at the Board's January meeting,
the Board voted 8-1 to reimburse Board
members for all Board-related work, includ-

ing mail ballots, review of Board packets,
review of committee packets, and attendance at committee meetings, with the
compensation to be based on the projected
estimated time; and unanimously rejected
a request from the Vietnamese Pharmacists Association to reconsider the Board's
Test of Spoken English (TSE) requirement
in section 1719, Title 16 of the CCR,
which requires that foreign-trained pharmacists pass the TSE prior to taking the
pharmacist licensure examination.
At the Board's March 30-31 meeting,
CPhA raised the issue of patients' rights to
"reasonable access" to pharmacists, in light
of numerous complaints from pharmacists
that health maintenance organizations and
health benefits plans are increasingly restricting their subscribers to the use of
certain pharmacies and excluding some
pharmacies from their networks. CPhA
Vice-President John Cronin argued that
patients are not receiving the full value of
their health insurance policies if they are
precluded from selecting where they want
to purchase prescriptions. Cronin suggested that the Board, the Department of
Corporations, the Department of Finance,
and the Department of Health Services
establish a task force with other affected
health care providers to establish a definition of the term "reasonable access."
However, Board members noted that the
Board is not authorized to take direct action on this issue; instead, the Board unanimously agreed to thank CPhA for its comments and extend the Board's support for
CPhA in its pursuit of a definition of the
term "reasonable access."
Also at the March meeting, the Board
discussed the discipline process for pharmacy technicians, noting that under the
Administrative Procedure Act, the procedure for disciplining pharmacy technicians is as procedurally complex as for
disciplining pharmacists. Among other
things, the Board discussed whether an
alternative method of registering technicians might lend itself better to discipline
and enforcement activities. The Board is
expected to continue its discussion of this
matter at a future meeting.
Also at its March meeting, the Board
noted the reassignment of DCA legal
counsel Robert Miller and the appointment of Chris Grossgart to serve as DCA
legal counsel for the Board; unanimously
agreed to write a letter of support to the
Medical Board of California (MBC) on
the issue of pain management (see agency
report on MBC for related discussion);
and unanimously agreed to establish an
eight-year term limit for members of its
Competency Committee, with no more
than two members changing each year.
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T

he Board of Registration for Profes-

sional Engineers and Land Surveyors
(PELS) regulates the practice of engineering and land surveying through its administration of the Professional Engineers Act,
sections 6700 through 6799 of the Business
and Professions Code, and the Professional Land Surveyors' Act, sections 8700
through 8805 of the Business and Professions Code. The Board's regulations are
found in Division 5, Title 16 of the California Code of Regulations (CCR).
The basic functions of the Board are to
conduct examinations, issue certificates,
registrations, and/or licenses, and appropriately channel complaints against registrants/licensees. The Board is additionally
empowered to suspend or revoke registrations/licenses. The Board considers the
proposed decisions of administrative law
judges who hear appeals of applicants who
are denied a registration/license, and those
who have had their registration/license suspended or revoked for violations.
The Board consists of thirteen members: seven public members, one licensed
land surveyor, four registered Practice Act
engineers and one Title Act engineer.
Eleven of the members are appointed by
the Governor for four-year terms which
expire on a staggered basis. One public
member is appointed by the Speaker of the
Assembly and one by the Senate Rules
Committee.
The Board has established four standing committees and appoints other special
committees as needed. The four standing
committees are Administration, Enforcement, Examination/Qualifications, and
Legislation. The committees function in
an advisory capacity unless specifically
authorized to make binding decisions by
the Board.
Professional engineers are registered
through the three Practice Act categories
of civil, electrical, and mechanical engi-

neering under section 6730 of the Business and Professions Code. The Title Act
categories of agricultural, chemical, control system, corrosion, fire protection, industrial, manufacturing, metallurgical,
nuclear, petroleum, quality, safety, and
traffic engineering are registered under
section 6732 of the Business and Professions Code.
Structural engineering and geotechnical engineering are authorities linked to
the civil Practice Act and require an additional examination after qualification as a
civil engineer.
On March 9, Governor Wilson appointed two new Board members who
subsequently joined PELS at its April 8
meeting. New public member Kathryn A.
Hoffman is a senior systems engineer for
an imaging technology firm, and structural engineer Hoi W. Wong is president
of the Sacramento firm of Hoi Wong and
Associates. Also on March 9, the Governor reappointed current Board President
Richard A. Johnson to another term on the
Board.

*MAJOR

PROJECTS

Oversight Hearing and Resulting
Legislation Prompt PELS Strategic
Planning Workshops. Following its November 1993 oversight hearing on PELS'
performance [14:1 CRLR 76-77], the
Senate Subcommittee on Efficiency and
Effectiveness in State Boards and Commissions released a report in which it concluded that all Department of Consumer
Affairs (DCA) occupational licensing agencies should be subject to a "sunset" legislative review process, and that PELS should
be merged with the Board of Registration
for Geologists and Geophysicists (BRGG).
Accordingly, Senator Dan McCorquodale
introduced SB 2036, which would establish a "sunset" mechanism for all DCA
agencies; several weeks later, he amended
SB 2038 to include a provision merging
BRGG and PELS.
In anticipation of a May 9 Business and
Professions Committee hearing on both
bills, representatives of both boards and
affected trade associations lobbied Senator McCorquodale and the members of the
Committee against the merger provision
in SB 2038. At the May 9 hearing, Committee members agreed to postpone the
merger of the two boards, but scheduled
them for early "sunset" review under SB
2036 (see LEGISLATION).
In the meantime, PELS scheduled a
February 25-26 "strategic planning session" designed to clarify its role, function,
and constituencies, and to address the criticisms leveled against it at the Senate Subcommittee hearing. The focus of much of
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the discussion at the retreat was the Center
for Public Interest Law's (CPIL) assertion
that PELS' engineering enabling statutes
and regulations are extremely vague and
in need of major restructuring and modernization; and Board President Rich Johnson's
November 1993 "white paper" entitled Confronting the Issues of Engineering Discipline Definitions, in which Johnson agreed
with CPIL that the Board's statutes are internally inconsistent and lack clarity. [14:1
CRLR 77] On this issue, the Board heard
presentations from representatives of state
engineering boards in New Jersey, Delaware, Wyoming, and Utah. Although
PELS members generally agreed that its
enabling act is in need of an overhaul and
discussed how aspects of the different approaches taken by these and other states
might be applied in California, they made
no specific plans to accomplish this goal.
At the workshop, the Board considered
for adoption the following mission statement: 'The mission of the Board of Registration for Professional Engineers and
Land Surveyors is to safeguard the life,
health, property, and public welfare by
regulating the practice of professional engineering and professional land surveying. We qualify and license individuals,
establish regulations, enforce laws and
regulations, [and] provide information so
that the public can make informed decisions." Additionally, the Board reviewed
a more detailed proposed vision statement,
and discussed multiple issues regarding its
regulatory framework and purpose.
Among other things, the Board set a
goal to advise all engineer and land surveyor applicants who file timely applications of acceptance or rejection within
sixty days of receipt of the application.
The Board also discussed instituting a
continuing education and/or retesting program (see below), and set a goal to implement a comprehensive program to ensure
continuing competency.
In response to CPIL's claim that more
than half of the consumer complaints received by the Board stem from the lack of
a written contract between the parties and
that PELS has failed to police billing
abuses within the industry, the Board discussed whether PELS staff should be involved in fee disputes between consumers
and engineers or land surveyors. Several
staff members noted that staff currently
involves itself informally in mediating fee
disputes. Several Board members opined
that staff should not be involved in this
capacity, and should leave such matters to
the courts. Although PELS has jurisdiction to deal cases involving breach of contract, these members contended that such
involvement by PELS is unfair to the en-

